FDA Requests Device Info for Novel Parkinson Disease Infusion Therapy
ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous delivery.
ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous delivery.
SPN-830 provides a continuous subutaneous infusion of apomorphine through an infusion pump
SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump.
The fixed-dose combination therapy was found to be superior to each component.
Counseling should be provided to individuals with early Parkinson disease on the benefits and risks of initiating treatment.
Patients are awake and responsive during the whole treatment duration.
The randomized, double-blind, double-dummy, active-controlled study compared ABBV-951 via continuous SC infusion to oral levodopa/carbidopa.
DA01 is an investigational pluripotent stem cell-derived dopaminergic neuron therapy designed to replace the midbrian dopaminergic neurons lost in Parkinson disease.